Market Research Logo

Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

Orphan diseases are typically life-threatening or chronically debilitating for which no or inadequate alternative treatments are available. An orphan disease refers to any rare disease which affects a smaller share of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.

Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.

Orphan drug market is likely to witness a growth in future with increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The US and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan drug designations. Asia is likely to experience further growth with increasing orphan designations in Japan and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends & development of this market include rise in orphan drug approvals, accelerating pipeline sales of orphan drugs, development of drug therapies and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.

The report “Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and Asia along with the global market. The report profiles key players of the market including Roche holding AF, Novartis International AG, Bristol-Myers Squibb and Celgene Corporation.


1. Overview
1.1 Orphan Disease
Table 1: Orphan Disease Prevalence in Different Nations
1.2 Orphan Drugs
Table 2: Types of Orphan Drugs
Table 3: Orphan Drug Development
2. Global Orphan Drugs Market
2.1 Global Orphan Drugs Market by Value
Table 4: Global Orphan Drugs Market by Value (2013-2017)
2.2 Global Orphan Drugs Market Forecast by Value
Table 5: Global Orphan Drugs Market Forecast by Value (2018-2022)
2.3 Global Orphan Drugs Market by Product
Table 6: Global Orphan Drugs Market by Product (2017)
2.3.1 Global Revlimid Drug Revenue Forecast
Table 7: Global Revlimid Drug Revenue Forecast (2017-2022)
2.3.2 Global Rituxan Drug Revenue Forecast
Table 8: Global Rituxan Drug Revenue Forecast (2017-2022)
2.3.3 Global Opvido Drug Revenue Forecast
Table 9: Global Opvido Drug Revenue Forecast (2017-2022)
2.4 Global Orphan Drugs Market by Therapy
Table 10: Global Orphan Drugs Market by Therapy (2017)
2.4.1 Global Oncology Therapy Market Forecast by Value
Table 11: Global Oncology Therapy Market Forecast by Value (2017-2022)
2.4.2 Global Blood Therapy Market Forecast by Value
Table 12: Global Blood Therapy Market Forecast by Value (2017-2022)
2.4.3 Global Central Nervous System Therapy Market Forecast by Value
Table 13: Global Central Nervous System Therapy Market Forecast by Value (2017-2022)
3. Regional Market Analysis
3.1 The Americas
3.1.1 The US Orphan Drugs Spending Forecast
Table 14: The US Orphan Drugs Spending Forecast (2017-2022)
3.1.2 The US Orphan Drug by Designation Volume
Table 15: The US Orphan Drug by Designation Volume (2013-2017)
3.1.3 The US Orphan Drug Average & Median Cost per Patient
Table 16: The US Orphan Drug Average & Median Cost per Patient (2013-2017)
3.1.4 The US Orphan Drug Average & Median Cost per Patient Forecast
Table 17: The US Orphan Drug Average & Median Cost per Patient Forecast (2018-2022)
3.1.5 Canada Orphan Drugs Spending
Table 18: Canada Orphan Drugs Spending (2013-2017)
3.1.6 Canada Orphan Drugs Spending Forecast
Table 19: Canada Orphan Drugs Spending Forecast (2018-2022)
3.2 Europe
3.2.1 Europe Orphan Drugs Market Forecast by Value
Table 20: Europe Orphan Drugs Market Forecast by Value (2017-2022)
3.2.2 Europe Orphan Drugs Market by Product
Table 21: Europe Orphan Drugs Market by Product (2017)
3.2.3 Europe Orphan Drug by Designation Volume
Table 22: Europe Orphan Drug by Designation Volume (2013-2017)
3.3 Asia
3.3.1 Japan Orphan Drug by Designation Volume
Table 23: Japan Orphan Drug by Designation Volume (2013-2017)
3.3.2 India Orphan Drugs Market Forecast by Value
Table 24: India Orphan Drugs Market Forecast by Value (2017-2022)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
Table 25: Orphan Drug Market Exclusivity
4.1.2 Increasing Sales of Prescription Drugs
Table 26: Global Prescription Drugs Sales (2013-2022)
4.1.3 Attractive Orphan Drug Policies
Table 27: Orphan Drug Policies
4.1.4 Rising Healthcare Expenditure
Table 28: Global Healthcare Expenditure (2013-2017)
4.1.5 Improving Economic Condition
Table 29: Global GDP Per Capita (2013-2017)
4.1.6 Increasing Prevalence of Chronic Diseases
Table 30: Global Cancer Prevalence (2012-2030E)
4.2 Key Trends & Development
4.2.1 Rise in Orphan Drug Approvals
Table 31: The US FDA Orphan Drug Approvals
(2010-2017)
Table 32: The US Orphan Novel Drug Approvals
(2010-2017)
4.2.2 Accelerating Pipeline Sales of Orphan Drugs
Table 33: Global Worldwide Orphan Drug Pipeline Sales (2018-2024)
4.2.3 Development of Drug Therapies
Table 34: Projection of Top 10 Orphan Drugs in Development (phase III/filed) by NPV* (2018)
4.3 Challenges
4.3.1 High Costs
Table 35: Prices and Prevalence of Some Orphan Drugs in the US (2017)
4.3.2 Lack of Diagnostic Systems and Trained Professionals
4.3.3 Insufficient Disease Information and Research Participants
4.3.4 Rising Competition from Generic Industry
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
Table 36: Key Players - Revenue & Market Cap Comparison (2017)
5.1.2 Global Orphan Drugs Market Share by Company
Table 37: Global Orphan Drugs Market Share by Company (2017/2024)
5.1.3 Global Oncology Orphan Drugs Market Share by Company
Table 38: Global Oncology Orphan Drugs Market Share by Company (2017/2024)
5.2 The US
5.2.1 The US Top 10 Orphan Drugs Sales by Company
Table 39: The US Top 10 Orphan Drugs Sales by Company (2017)
5.3 Europe
5.3.1 Europe Orphan Drugs Market Share by Company
Table 40: Europe Orphan Drugs Market Share by Company (2017)
6. Company Profiles
6.1 Novartis International AG
6.1.1 Business Overview
Table 41: Novartis Sales by Segment (2017)
6.1.2 Financial Overview
Table 42: Novartis Net Sales and Net Income (2013-2017)
6.1.3 Business Strategies
Table 43: Novartis Agreements (2018)
Table 44: Novartis Major Product Approvals (2018)
6.2 Roche Holding AG
6.2.1 Business Overview
Table 45: Roche Sales by Segments (2017)
6.2.2 Financial Overview
Table 46: Roche Sales and Net Income (2013-2017)
6.2.3 Business Strategies
Table 47: Roche Agreements (2017/2018)
Table 48: Roche Product Approvals (2018)
6.3 Bristol-Myers Squibb
6.3.1 Business Overview
Table 49: Bristol-Myers Squibb Revenue by Region (2017)
6.3.2 Financial Overview
Table 50: Bristol-Myers Squibb Total Revenue and Net Earnings (2013-2017)
6.3.3 Business Strategies
Table 51: Bristol-Myers Squibb R&D Expenditure (2015-2017)
Table 52: Bristol-Myers Squibb Agreements (2018)
6.4 Celgene Corporation
6.4.1 Business Overview
Table 53: Celgene Revenue by Region (2017)
6.4.2 Financial Overview
Table 54: Celgene Total Revenue and Net Income (2013-2017)
6.4.3 Business Strategies
Table 55: Celgene R&D Expenditure (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report